Memahami Uji Klinis Paxlovid untuk Covid-19
DOI:
https://doi.org/10.32583/far.v12i3.1250Keywords:
COVID-19, paxlovid, randomized controlled trial, tinjauan sistematisAbstract
Pada 17 Maret 2022 Perserikatan Bangsa-Bangsa mendukung dan menandatangani perjanjian dengan 35 produsen obat generik di Eropa, Asia, dan Amerika agar memproduksi Paxlovid untuk pengobatan COVID-19. Indonesia telah bersiap untuk menerima paxlovid sebagai alternatif treatment COVID-19. Namun, informasi tentang paxlovid dan uji klinis yang telah dilakukannya belum banyak tersedia dalam bahasa Indonesia. Berdasarkan latar belakang tersebut, penulis tertarik untuk melakukan tinjauan sistematis guna memberikan informasi dan pandangan tentang penggunaan paxlovid dalam terapi COVID-19 agar berguna bagi teman sejawat farmasi dalam mengetahui perkembangan pengobatan dan antivirus COVID-19. Metode penelitian ini adalah Artikel dicari melalui basis data sejak Januari – Juli 2022 . Melalui database PUBMED, Science direct, dan Google Scholar. Kata kunci yang digunakan adalah "Nirmatlevir AND COVID-19” AND “Ritonavir AND COVID-19” "Paxlovid AND COVID-19”. Populasi dalam hal ini adalah pasien terinfeksi COVID-19 dari hasil real time PCR. Design studi yang digunakan adalah clinical trial. Data yang telah tersaring disajikan dalam tabel alur sesuai denan item PRISMA. Hasil yang didapat adalah terdapat 8 artikel yang memenuhi syarat kualitatif untuk dibahas. 5 artikel menyimpulkan bahwa paxlovid memiliki keunggulan dalam treatment COVID-19. 2 artikel menyimpulkan bahwa paxlovid tidak lebih signifikan dari arbitol. Sedangkan 1 artikel menyimpulkan tidak ada perbedaan dalam efek treatment antara kelompok paxlovid dan kelompok control. Kesimpulan dari penelitian ini adalah Paxlovid menjanjikan efek pengobatan karena terbukti gabungan nirmatlevir dan ritonavir dapat memblokir SARS-CoV-2 Mpro, sehingga tidak bisa mengikat poliprotein, hal itu membuat virus tidak bisa membuat protein fungsional apa pun. Meski demikian penggunaan paxlovid masih bersifat darurat dan masih perlu uji klinis lebih lanjut bila ingin digunakan dalam jangka panjang.
References
Ahmad, B. et al., 2021. Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations. International Journal of Molecular Sciences, 22(17).
Anon, 2022. Pfizer COVID-19 antiviral paxlovid authorised by MHRA. Pharmaceutical Journal.
Arabi, Y.M. et al., 2021. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 47(8), pp.867–886. Available at: https://doi.org/10.1007/s00134-021-06448-5.
Atmojo, J. T., Arradini, D., Ernawati, E., Widiyanto, A., & Darmayanti, A. T. (2020). Cardiopulmonary Resuscitation in the Covid-19 Pandemic Era. Jurnal Keperawatan, 12(3), 355-362.
Atmojo, J. T., Hanifah, L., Handayani, R. T., Rejo, R., Setyorini, C., Widyaningrum, N. R., ... & Mubarok, A. S. (2021). Efektivitas Masker Medis dalam Mencegah Penularan COVID-19. Avicenna: Journal of Health Research, 4(2).
Bethany Halford, 2022. How Pfizer scientists transformed an old drug lead into a COVID-19 antiviral. Chemical & Engineering News, pp.16–18.
Chen, C. et al., 2021. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Frontiers in Pharmacology, 12.
Cozzupoli, G.M. et al., 2020. Possible Retinal Impairment Secondary to Ritonavir Use in SARS-CoV-2 Patients: A Narrative Systematic Review. Journal of Ophthalmology, 2020.
Drożdżal, S. et al., 2021. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resistance Updates, 59.
Extance, A., 2022. Covid-19: What is the evidence for the antiviral molnupiravir? The BMJ, (February 2020), pp.2020–2022.
Fishbane, S., Hirsch, J.S. & Nair, V., 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect , the company â€TM s public news and information . , (January), pp.2020–2023.
Hammond, J. et al., 2022. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine, 386(15), pp.1397–1408.
Hung, Y.P. et al., 2022. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Antibiotics, 11(2), pp.5–11.
Jayk Bernal, A. et al., 2022. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine, 386(6), pp.509–520.
Jin, Z. et al., 2020. Structure of M<sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), pp.289–293. Available at: https://dx.doi.org/10.1038/s41586-020-2223-y.
Jun, C. et al., 2020. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chinese Journal of Infectious Diseases, 38(0), pp.E008–E008.
Li, Y. et al., 2020. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med, 1(1), p.105–113.e4.
Liberati, A. et al., 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj, 339(jul21 1), pp.b2700–b2700. Available at: http://www.bmj.com/cgi/doi/10.1136/bmj.b2700.
Mahase, E., 2021. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ (Clinical research ed.), 375, p.n2713.
Najjar-Debbiny, R. et al., 2022. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clinical Infectious Diseases, pp.1–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Meliana Novitasari, Kiki Puspitasary, Nova Rahma Widyaningrum, Aquartuti Tri Darmayanti, Aris Widiyanto, Ahmad Syauqi Mubarok, Joko Tri Atmojo
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
